Eimear Flanagan

610 total citations
6 papers, 371 citations indexed

About

Eimear Flanagan is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Eimear Flanagan has authored 6 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Immunology and 2 papers in Molecular Biology. Recurrent topics in Eimear Flanagan's work include Cancer Immunotherapy and Biomarkers (5 papers), Cancer, Stress, Anesthesia, and Immune Response (2 papers) and Immune cells in cancer (2 papers). Eimear Flanagan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Cancer, Stress, Anesthesia, and Immune Response (2 papers) and Immune cells in cancer (2 papers). Eimear Flanagan collaborates with scholars based in United Kingdom, Netherlands and Italy. Eimear Flanagan's co-authors include Victoria S. Pelly, Charlotte R. Bell, Santiago Zelenay, Agrin Moeini, Christian P. Bromley, Shih‐Chieh Chiang, Eduardo Bonavita, Antonia Banyard, Ton N. Schumacher and Gustav Jonsson and has published in prestigious journals such as Nature Communications, Immunity and Cancer Discovery.

In The Last Decade

Eimear Flanagan

5 papers receiving 369 citations

Peers

Eimear Flanagan
Charlotte R. Bell United Kingdom
Colin Hutton United Kingdom
Sylvie Roques France
Pingqing He China
Sofía Bruni Argentina
Anja Schmall Germany
Atefeh Ghahremanloo Iran
Afshin Nikkhoo Iran
Nada S. Aboelella United States
Sandipto Sarkar United States
Charlotte R. Bell United Kingdom
Eimear Flanagan
Citations per year, relative to Eimear Flanagan Eimear Flanagan (= 1×) peers Charlotte R. Bell

Countries citing papers authored by Eimear Flanagan

Since Specialization
Citations

This map shows the geographic impact of Eimear Flanagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eimear Flanagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eimear Flanagan more than expected).

Fields of papers citing papers by Eimear Flanagan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eimear Flanagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eimear Flanagan. The network helps show where Eimear Flanagan may publish in the future.

Co-authorship network of co-authors of Eimear Flanagan

This figure shows the co-authorship network connecting the top 25 collaborators of Eimear Flanagan. A scholar is included among the top collaborators of Eimear Flanagan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eimear Flanagan. Eimear Flanagan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
Flanagan, Eimear, Richard Armer, Clifford D. Jones, et al.. (2022). The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models. Cancer Research Communications. 2(9). 914–928. 19 indexed citations
2.
Bell, Charlotte R., Victoria S. Pelly, Agrin Moeini, et al.. (2022). Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations. Nature Communications. 13(1). 2063–2063. 76 indexed citations
3.
Cook, Natalie, Sarah P. Blagden, Juanita Lopez, et al.. (2022). 719 Phase 1 study of the porcupine (PORCN) inhibitor RXC004 in combination with the PD-1 inhibitor nivolumab in patients with advanced solid tumors. Regular and Young Investigator Award Abstracts. A752–A752. 2 indexed citations
4.
Pelly, Victoria S., Agrin Moeini, Lisanne M. Roelofsen, et al.. (2021). Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy. Cancer Discovery. 11(10). 2602–2619. 117 indexed citations
5.
Bonavita, Eduardo, Christian P. Bromley, Gustav Jonsson, et al.. (2020). Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade. Immunity. 53(6). 1215–1229.e8. 157 indexed citations
6.
Kononov, Alexander, Joanna Kelly, Jingshu Xu, et al.. (2019). Tumour Cell Heterogeneity Instructs Fibroblast Diversity and Reciprocal Signalling. SSRN Electronic Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charlotte R. Bell Breakdown of academic impact, for papers by Colin Hutton Breakdown of academic impact, for papers by Sylvie Roques Breakdown of academic impact, for papers by Pingqing He Breakdown of academic impact, for papers by Sofía Bruni Breakdown of academic impact, for papers by Anja Schmall Breakdown of academic impact, for papers by Atefeh Ghahremanloo Breakdown of academic impact, for papers by Afshin Nikkhoo Breakdown of academic impact, for papers by Nada S. Aboelella Breakdown of academic impact, for papers by Sandipto Sarkar
Rankless by CCL
2026